SERVICES FRAME AGREEMENT
Between
Pfizer, Inc. and Theranos, Inc
December 15, 2006

This Agreement is entered into as of November 22, 2006 by and between **Pfizer Inc**, a Delaware corporation with a business address of 235 East 42nd Street, New York, NY 10017 (together with its Affiliates "Pfizer"), and Theranos, Inc. with an office at 1430 O'Brien Drive, Suite C, Menlo Park, California, 94025, USA.

Whereas, Pfizer is a pharmaceutical company possessing proprietary and confidential information related to drug development and potential drug targets and biomarkers; and

Whereas, Theranos is a technology company possessing expertise in assay development and data collection;

Whereas, both parties wish to enter into an evaluation of Theranos technology to determine its application to Pfizer's drug development efforts;

Now therefore, in consideration of the foregoing and mutual promises contained herein and to set forth a clear understanding of the mutual rights and obligations relating to it, the parties agree as follows:

1. GENERAL SCOPE OF AGREEMENT

1.1. Theranos will perform studies for feasibility, assay and informatics development, assay validation and sample measurement and other agreed services set forth in the Study Plan attached as Exhibit 1. Theranos will provide all personnel and equipment reasonably necessary to perform the Services. Theranos will not perform any work for Pfizer beyond the Study Plan without the prior written approval of Pfizer.

1.2. The parties shall regularly communicate about all relevant matters with regard to the Study Plan, in a form and manner as the parties shall mutually agree. Theranos shall promptly inform Pfizer about any material unforeseen results, problems or difficulties with regard to the Study Plan which are reasonably likely to result in a significant delay in any timetable set forth in Exhibit 1.

1.3. Theranos warrants that its employees and permitted sub-contractors who are involved in performing the Study Plan will comply with the applicable obligations of Theranos hereunder.

2. TERM OF AGREEMENT

2.1. The Term of this Agreement will be until the conclusion of the Study Plan agreed in Exhibit 1, unless earlier terminated in accordance with Section 9 of this Agreement.

3. TEST SAMPLES

3.1 Subject to the provisions in Exhibit 1, Pfizer shall, at its own cost, deliver to Theranos free of charge certain Pfizer materials (the "Test Samples"), as mutually agreed by the parties and specified in Exhibit 1. Pfizer shall deliver an amount of the Test Samples sufficient to enable Theranos to perform the Study Plan to which the Test Samples relate.

3.2 Prior to receipt by Theranos of the Test Samples, Pfizer shall provide Theranos with any and all procedures and warnings which are known to Pfizer and are necessary and/or desirable to help assure the safe handling and use of the Test Samples. Theranos, however, accepts the Test Samples with the understanding that their hazardous and toxicological properties may not have been completely investigated and therefore are unknown. Theranos will handle the Test Samples accordingly and will inform Pfizer in writing of any adverse affects experienced by persons handling the Test Samples.

3.3 Theranos will use the Test Samples solely for the purpose of performing the Study Plan in Exhibit 1. In addition, Theranos shall not modify the Test Samples (except as agreed by the parties) or administer it to any animals or humans or supply the Test Samples to any third party other than an Affiliate or permitted sub-contractor, without the consent of Pfizer. Affiliate for the purpose of this Agreement shall mean any corporation or other business entity that is Controlled by, Controlling or under common Control with a party. "Control" for the purpose of this definition shall mean direct or indirect beneficial ownership of fifty percent (50%) or more of the voting interest in an entity, or the power to direct the management and policies of such corporation or other business entity, or such other relationship that in fact constitutes actual control.

4. PAYMENT TERMS

PAYMENT: Pfizer will pay to Theranos the sum of nine hundred thousand dollars ($900,000.00) according to the following payment schedule:

(i) Pfizer will pay to Theranos the sum of five hundred thousand dollars ($500,000.00) within thirty (30) days of the execution of this Agreement.

(ii) Pfizer will pay to Theranos the sum of three hundred thousand dollars ($300,000.00) upon submission of an interim report of assay development completion.

(iii) Pfizer will pay to Theranos the sum of one hundred thousand dollars ($100,000.00) upon receipt of a final report from Theranos.

(iv) After the execution of this Agreement, Pfizer will issue a purchase order number to Theranos. Theranos will invoice Pfizer for payment due to Theranos using the issued purchase order number. The purchase order number must appear on each invoice. Theranos will be responsible for invoicing Pfizer at the successful completion of each milestone listed above, including the first payment due upon execution of this agreement.

Invoices should be submitted to:

Strategic Alliances
Pfizer Inc
50 Pequot Avenue
MS 6025-C4120
New London, Ct. 06320
Attn: Head of Development and Commercial Strategic Alliances

5. INTELLECTUAL PROPERTY

5.1. All information, data and writings, inventions and other intellectual property provided to Theranos by and/or on behalf of Pfizer in connection with this Agreement, in any form whatsoever, both tangible and intangible, which were owned by or licensed to Pfizer prior to being provided to Theranos, shall remain the sole and exclusive property of Pfizer (the "Pfizer Data"). Theranos shall acquire no right, title or interest in the Pfizer Data as a result of its performance of the Study Plan except as expressly provided in this Agreement. Pfizer hereby grants to Theranos a non-exclusive, worldwide, royalty-free license (including the right to grant sublicenses in accordance with this Agreement) to use any Pfizer Data that may be necessary or reasonably useful in connection with the performance of any work under the Study Plan.

5.2. All information, data, writings, inventions and other intellectual property, in any form whatsoever, both tangible and intangible, owned by or licensed to Theranos prior to the commencement of this Agreement, or following the commencement date of this Agreement but prior to the commencement date of the Study Plan shall remain the sole and exclusive property of Theranos ("Theranos Background Technology"). For clarity, Theranos Background Technology shall include all inventions and other intellectual property relating to the Cartridges, the Readers, the ABCS and Theranos System, as each such term is defined in Exhibit. 2 attached to this Agreement and dated as of the date hereof.

5.3 The ownership of any information, data, writings, inventions and other intellectual property developed by Theranos (or its employees and subcontractors) as a result of Theranos' performance of the Study Plan shall be determined in accordance with the provisions of the Study Plan.

5.3. After completion of the Study Plan or the termination of this Agreement: (a) upon the request of Pfizer, Theranos shall return to Pfizer all Pfizer Data and any other items specified in Exhibit 1; provided that Theranos shall not be obligated to return any Pfizer Data or other intellectual property assigned to Theranos by Pfizer under the Study Plan; and (b) upon the request of Theranos, Pfizer shall return to Theranos all Theranos Background Technology and any other items specified in Exhibit 2.

5.4. Theranos represents that, to its knowledge, it owns or has the right to use all copyright, trademark, patents, and other intellectual property rights included in Theranos Background Technology which, as of the date of commencement of this Agreement, it intends to use to perform its obligations under this Agreement.

5.5. Theranos shall acquire no right, title or interest in any of the trademarks, service marks or copyrights belonging to Pfizer, nor shall it be deemed to have made any trademark usage of any trademarks by the performance of any Services for Pfizer hereunder, except as expressly provided in this Agreement.

6. CONFIDENTIAL INFORMATION/PUBLICATION

6.1. Each party ("receiving party") agrees to maintain in confidence and not to publish, disclose or use for any purpose other than this Agreement, any and all confidential information, in any form whatsoever, disclosed by the other party ("disclosing party") in connection with this Agreement (collectively for each disclosing party, "Information"). Information shall include without limitation all confidential information disclosed to a party by the other party's Affiliates. The obligations under this Section 6 of non-disclosure and non-use shall not apply to the extent that:

(a) Information of a disclosing party at or after such time that it is or becomes publicly available through no fault of the receiving party;

(b) Information that is already independently known to the receiving party as shown by written records existing at the time of such disclosure;

(c) Information at or after such time that it is disclosed to the receiving party by a third party with the legal right to do so; or

(d) Information required to be disclosed by the receiving party pursuant to judicial process, court order or request of any governmental body, provided that the receiving party shall so notify the disclosing party sufficiently prior to disclosing such Information so as to permit the disclosing party to seek a protective order or otherwise prevent or restrict such disclosure.

Notwithstanding the foregoing, a receiving party may disclose Information of the disclosing party to any of its Affiliates, employees, consultants, agents, or

any permitted subcontractors or sub-subcontractors retained to assist the receiving party in the performance of the Study Plan, on a need-to-know basis in accordance with the receiving party's exercise of its rights or performance of its obligations under this Agreement, provided that the receiving party has first obtained written agreement from any such persons to maintain the confidentiality of, and not to use, such Information pursuant to terms not less strict than those set forth in this Agreement.

6.2. Theranos shall not make any publications relating solely to the Study Plan or containing any Information about Pfizer products ("Pfizer Materials") without Pfizer's written consent.

6.3. Each party's obligations under this Section 6 shall survive the expiry or termination of this Agreement for 10 (ten) years.

7. PUBLICITY

7.1. Neither party shall disclose that Pfizer has entered into this Agreement with Theranos; provided however that Theranos may disclose that Pfizer has entered into this Agreement to: (a) Theranos's advisors, existing and potential investors and others on a need-to-know basis, in each case under obligations of confidentiality and non-use which are not less strict than those set forth in this Agreement

7.2. Neither party will use, or authorise others to use, the name, symbols, or marks of the other party in any advertising or publicity material or make any form of representation or statement with regard to the Services which would knowingly constitute an express or implied endorsement by the other party of any commercial product or service without that other party's prior written approval.

8. **INDEMNIFICATION:** Pfizer shall defend, indemnify and hold harmless Theranos, its employees, directors, trustees and officers, from and against any and all liability which it may incur by reason of Pfizer's use of the results of the work; provided, however, that Theranos shall indemnify Pfizer, its employees, consultants, directors and officers for any claims for injuries to persons or damages which occur on Theranos's premises or premises under the control of Theranos while performing work.

9. **TERMINATION:** Pfizer may terminate this Agreement with or without cause by giving forty five (45) days notice to Theranos in writing. If Pfizer terminates this Agreement, Pfizer's only obligation shall be to pay Theranos for the work performed up to the date of termination and any

costs incurred to close down the project

10. CONFORMANCE WITH LAW AND ACCEPTED PRACTICE

10.1. Theranos shall perform the Study Plan:

(a) In a timely and professional manner;

(b) In conformance with that level of care and skill ordinarily exercised by other professional companies of a similar size and in similar circumstances; and

(c) In compliance in all material respects with all applicable laws, regulations and guidelines relating to the Study Plan.

10.2. Theranos warrants that it presently has not, and shall not for the term of this Agreement and any mutually agreed extension thereof, grant to any third party rights in Theranos Background Technology that are inconsistent with the rights granted to Pfizer under this Agreement.

10.3 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT OR ANY WORK ORDER, THERANOS MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THERANOS BACKGROUND TECHNOLOGY, OR THE SERVICES OR ANY ITEMS OR WORK PRODUCT PROVIDED UNDER ANY WORK ORDER, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF ANY INTELLECTUAL PROPERTY OF THERANOS OR NONINFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

11. SUBCONTRACTORS

Theranos shall not retain any sub-contractor to assist Theranos in performing the Study Plan without the prior written approval of Pfizer, such approval not to be unreasonably withheld. Any such approval shall not relieve Theranos of its obligations under this Agreement.

12. INDEPENDENT CONTRACTOR

12.1. Theranos shall perform the Study Plan as an independent contractor and, as such, neither Theranos nor its employees shall be entitled to any benefits applicable to employees of Pfizer.

12.2. Neither party is authorised or empowered to act as agent for the other for any purpose and shall not on behalf of the other enter into any contract, warranty or representation or commitment of any kind as to any matter, without the prior written approval of the other party.

13. ENTIRE AGREEMENT

This Agreement, and the attached Exhibits 1 and 2 attached hereto, represent the entire agreement and understanding of the parties with respect to the subject matter hereof and supersedes all prior discussions, agreements and writings in respect hereto. None of the terms of this agreement shall be amended except in writing signed by both parties.

14. SEVERABILITY

The invalidity, illegality or unenforceability of any term or provision of this Agreement shall not affect the validity, legality or enforceability of any other term or provision hereof and such invalid, illegal or unenforceable provision shall be reformed to comply with applicable law or stricken if not so conformable.

15. ASSIGNMENT

Neither party hereto may assign or transfer any of its rights or obligations under this Agreement without the prior written consent of the other party, which consent may not be unreasonably withheld; provided that, without such consent, either party may assign this Agreement in connection with the transfer or sale of all or substantially all of its assets or business to which this Agreement relates or its merger or consolidation with another company. Pfizer may assign this Agreement in whole or in part to any Affiliate without the consent of Theranos, and shall provide written notice to Theranos promptly following any such assignment. No assignment shall relieve either party of the performance of any accrued obligation which such party may then have under this Agreement. Any assignment or transfer of this Agreement, or any of a party's rights or obligations hereunder, in violation of this Section 15 shall be void.

16. WAIVER

Any term of this Agreement may be waived only by a written instrument executed by a duly authorized representative of the party waiving compliance. No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in any one or more instances shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition, or of any other term, provision or condition of this Agreement.

17. FORCE MAJEURE

Neither party shall be liable for non-fulfilment of its obligations hereunder if such non-fulfilment is due to strikes, riots, war, invasion, acts of God, fire, explosion, floods, acts of government agencies (other than such acts which are the result of an act or omission of the party seeking to rely upon this Section 17), judicial action, labour disturbance and/or any other event beyond that party's reasonable control.

18. APPLICABLE LAW AND VENUE

This Agreement shall be governed by, and construed in accordance with the laws of New York, except as they relate to the conflict of laws.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly authorized representatives as of the day and year first above written.

PFIZER, Inc.

(signature)

B. J. Berman
(name printed)

V. P., Strategic Alliances
(title)

December 11, 2006
(date)

THERANOS, INC.

(signature)

ELIZABETH HOLMES
(name printed)

PRESIDENT & CEO
(title)

DECEMBER 12, 2006.
(date)

This Page Intentionally Blank

Exhibit 1—Study Plan for the Technical Assessment of Theranos System

Pfizer is sponsoring a technical assessment of the Theranos System by utilizing cartridges designed to run assays for VEGF and PLGF. The Theranos System will be incorporated into the study outlined below.

Goals of Study:

1. Generate preliminary data on VEGF and PLGF trends in cancer patients while assessing the use of the Theranos System in the hands of clinicians and patients.
2. Obtain feedback and recommendations from clinical staff.
3. Assess the use of the Theranos System in the hands of ambulatory patients at home.
4. Assess the Ambulatory Bioinformatics Communications System including the physician and patient web portals as well as the data reports generated.

The details of this proposed protocol follow:

1. **Oncology Center(s):** Up to 3 Sites
2. **Expected Start Date**: December, 2006
3. **Type of Study**: On-site/In-home; Open Label, data comparison; current standard laboratory measurements *vs* real-time measurements using the Theranos System. Blood is monitored at baseline and periodically during the study.
4. **Patient Profile:** 60 patients with confirmed solid-tumor cancers such as colorectal, renal, NSCLC, etc. Patients should represent the spectrum of patients from adjuvant through to stage 4. For this study, a minimum of 10 adjuvant patients should be recruited.
5. **Indication**: Cancer (Confirmed solid-tumor cancers including colorectal, renal cancer, GIST, NSCLC. Etc.)
6. **Inclusion/Exclusion Criteria**: TBD with Investigator(s)
7. **Estimated Duration**: 14 data points as per Table 1
8. **Number of Patients**: Total 60 (males and females)
9. **Number of Readers**: 72 (1 Reader per patient per site plus 12 extra for use in clinic
10. **Number of Cartridges**: Total of 1140 cartridges;
    a. 17 cartridges per patient protocol = 840 total
    b. 3 extra cartridges per patient = 210
    c. 2 extra cartridges per patient at clinic = 140
11. **Statistics**: a) Plot/Correlation between levels of soluble selected biomarkers using the Theranos System and the conventional laboratory (ELISA or other) method; b) integrated analysis of real time data, patient diary inputs, and static information in the patient record.
12. **Other Requirements**:
    a. Where available, results of patient PET scans will be collected within the ABCS system.
    b. Each patient involved in the pilot will be sent home with a Reader and individual cartridges. The clinical personnel will need to use the supplied bar code scanner to scan the individual bar

codes for each cartridge and link it with a patient ID which will be entered via a screen within ABCS. The patients will also be supplied with the appropriate number of lancets and alcohol wipes. A tote bag will be supplied for each patient to carry their cartridges and accessories home.

Clinical Trial Design - The following clinical trial design will be incorporated into an approved protocol.

Prior to Study Initiation

1. Clinical Site will recruit patients for participation in this clinical trial. Upon agreement to participate the patients will have a venous blood draw sent to the laboratory for conventional evaluation. The frozen sample, the raw data and analyte concentrations from the laboratory evaluation should be sent to Theranos prior to the initiation of the study for creation of calibration curves.

Pilot Study

1. On the first clinic visit clinical personnel will draw venous blood from the patient and send the blood to the laboratory for conventional evaluation.

2. The designated clinical personnel will then demonstrate to the patient how to use the Theranos System. Designated clinical personnel will oversee the patient as they use a lancet to draw blood through a finger prick, use the Cartridge to draw in the blood sample and insert the cartridge into the reader. While the reader runs the analysis on that cartridge, the patient will be provided a Patient User Manual and instructed on the other aspects of their clinical trial and their therapies. The patients will also be taken through how to access the web site and the patient diary and how to record required information. After going through the patient diary, patients will return to the reader, dispose of the Cartridge and then use a second the Cartridge by repeating the process of drawing a blood sample and inserting the cartridge into a reader. Each patient will then leave the clinic with a Theranos reader and eight Theranos cartridges. Results from the finger prick assays will be compared to results from the venous blood draw.

3. The patient will take all medications as prescribed, and will record the following information into the patient diary (Appendix A) each day:
   a. Medicines taken including time of day and dose
   b. Overall health assessment; how do they feel that day and are they experiencing any side effects
   c. The Patient Diary will be finalized with Pfizer prior to the initiation of the study.

4. On Day 4 each patient will utilize the Theranos System as trained in step #3. The cartridge will be used to draw in the blood sample and cartridge with blood will be inserted into the reader. After the reader performs the analysis, the patient will dispose the used cartridge.

5. On Day 7, 10, 13 and 16 the patient will repeat this process

6. On Day 19 each patient will return to the clinic where clinical personnel will do a venous blood draw for analysis in the lab and will oversee the patient taking a finger stick and inserting the cartridge into the Theranos Reader for comparison to the laboratory test.

7. On Day 37, the patient will return to the clinic for their final visit as part of this study. The patients will return with their reader and will utilize a finger stick for the Theranos System and patients will have a final venous blood draw.

The complete outline of the patients monitoring process is laid out in the following table.

Table 1: Data Points for Clinical Monitoring using Theranos System (TS) and Laboratory (ELISA)

Data Point	Location	Assay
Day 1	Clinic	2 TS cartridges ELISA
Day 4	Home	TS
Day 7	Home	TS
Day 10	Home	TS
Day 13	Home	TS
Day 16	Home	TS
Day 19	Clinic	1 TS cartridge ELISA
Day 22	Home	TS
Day 25	Home	TS
Day 28	Home	TS
Day 31	Home	TS
Day 34	Home	TS
Day 37	Clinic	1 TS cartridge ELISA

Deliverables

1. Theranos System Evaluation
    a. Investigators – Clinic participants in the assessment will be asked to complete an evaluation of the Theranos System upon completion of the study. A draft of this questionnaire will be developed and approved by Pfizer prior to the initiation of the study.
    b. Patients – Patients will be asked to complete an evaluation of the Theranos System upon completion of the study. A draft of this questionnaire is attached in Appendix B but will be finalized and approved by Pfizer prior to the initiation of the study.

2. Theranos will provide a study report at the conclusion of the assessment. This report will include:
    a. Complete review of the data generated in aggregate and by patient sub-types such as cancer type, sex, etc.
    b. Integrated patient information including time of day when monitoring was performed, other medications, overall health rating, etc.
    c. Assessment of the technical performance of the Theranos System including the following metrics:
        i. Wireless Transmission - % success, identification of problems and solutions
        ii. Overall, performance of the Theranos System determined by customer service log maintained during the assessment.
        iii. Patient Compliance versus protocol.
    d. Summary of patient and clinical team assessment of Theranos System.

Appendix A – Patient Diary

Initial Questionnaire – Completed by Clinic Staff

1. Please fill in the following information:
    a. Patient Age _____
    b. Patient Height_____
    c. Patient Weight_____
    d. Demographics
        1. Caucasian
        2. Black
        3. Hispanic
        4. Asian
        5. Other

2. Which of the following best describes your smoking status?
    a. I smoke daily
    b. I smoke occasionally
    c. I don't smoke now, but I used to
    d. I have tried it a few times, but never smoke regularly
    e. I have never smoked

3. How often do you usually have an alcoholic drink of any kind? This includes wine, beer and spirits.
    a. Every day
    b. 4-6 times per week
    c. 1-3 times per week
    d. Monthly or less
    e. I don't drink alcohol at all

4. How often do you exercise:
    a. Every day
    b. 4-6 times a week
    c. 2-3 times a week
    d. Once a week
    e. Less than once a month
    f. Never

5. What is the primary diagnosis the patient is being treated for:
    a. Colorectal Cancer
        i. Adjuvant
        ii. Metastatic
            1. Stage? II, III. IV
    b. GIST
        i. Adjuvant
        ii. Metastatic
            1. Stage? II, III. IV
    c. Renal Cancer
        i. Adjuvant
        ii. Metastatic
            1. Stage? II, III. IV
    d. Breast Cancer
        i. Adjuvant
        ii. Metastatic
            1. Stage? II, III. IV
    e. NSCLC

i. Adjuvant
ii. Metastatic
1. Stage? II, III. IV

f. Other
i. Adjuvant
ii. Metastatic
Metastatic
1. Stage? II, III. IV

2. Please check all the medications the patient is currently being given:

Chemotherapies		
5-FU	fluorouracil	
Camptosar	irinotecan/CPT-11	
Eloxatin	oxaliplatin	
Gemzar	gemcitabine	
Hycamtin	Topotecan	
Paraplatin	carboplatin	
Xeloda	Capecitabine	
	leucovorin	
Other Chemotherapy		

General Therapies		
Anastrozole	arimidex	
Avastin	bevacizumab	
Bexxar		
Erbitux	cetuximab	
Gleevec		
Herceptin	Gemcitabine	
Iressa	Gefitinib	
Nexavar	sorafenib	
Revlimid	LENALIDOMIDE	
Sutent	sutinib malate	
Tarceva	Erlotinib	
Taxotere	Docetaxel	
Velcade	Bortezomib	
Other General Therapies		

Supportive Care		
Advil/other	ibuprofen	
Ambien/Lunesta/other sleep aids		
Anzament	dolasetron	
Aranesp	Erythropoietin	
Aspirin		
Epogen	Erythropoietin	
Kytril	granisetron	
Neulasta	pegfligrastim	
Neupogen	Filgrastim	
Paxil/other antidepressants		
Procrit	Erythropoietin	
Tylenol/other	acetaminophen	
Zofran	ondansetron	
Other Supportive Care		

Daily Questions

1. On a scale of 1 to 10, how do you feel today?

   Very Good 10 9 8 7 6 5 4 3 2 1 Poor

2. Please check if you have any of these complaints today:
   a. Headache
   b. Nausea
   c. Body Pain
   d. Dizziness
   e. Reaction at infusion site
   f. Fatigue
   g. Depressed
   h. Shortness of breath
   i. Decreased appetite

3. Thinking about your health today, which of the following statements best describe your usual activities such as work, family or leisure activities.
   j. I have no problems with performing my usual activities
   k. I have some problems performing my usual activities
   l. I am unable to perform my usual activities.

4. Did you exercise in the last 24 hours?
   m. No
   n. Yes
      1. What kind of exercise did you do? Mark all that apply
         - Walk
         - Run/Jog
         - Bike
         - Swim
         - Weights
         - Yoga
         - Pilates
         - Golf
         - Tennis
         - Other
      2. How long did you exercise?
         - Less than 30 minutes
         - 30 minutes to 1 hour
         - Over 1 hour

5. Please indicate the medications you took/received today and the time you took each medication.

Chemotherapies		Time
5-FU	fluorouracil	
Camptosar	irinotecan/CPT-11	
Eloxatin	oxaliplatin	
Gemzar	gemcitabine	
Hycamtin	Topotecan	
Paraplatin	carboplatin	
Xeloda	Capecitabine	
	leucovorin	
Other Chemotherapy		

General Therapies		
Anastrozole	arimidex	
Avastin	bevacizumab	
Bexxar		
Erbitux	cetuximab	
Gleevec		
Herceptin	Gemcitabine	
Iressa	Gefitinib	
Nexavar	sorafenib	
Revlimid	Lenalidomide	
Sutent	sutinib malate	
Tarceva	Erlotinib	
Taxotere	Docetaxel	
Velcade	Bortezomib	
Other General Therapies		

Supportive Care		
Advil/other	ibuprofen	
Ambien/Lunesta/other sleep aids		
Anzament	dolasetron	
Aranesp	Erythropoietin	
Aspirin		
Epogen	Erythropoietin	
Kytril	granisetron	
Neulasta	pegfligrastim	
Neupogen	Filgrastim	
Paxil/other antidepressants		
Procrit	Erythropoietin	
Tylenol/other	acetaminophen	
Zofran	ondansetron	
Other Supportive Care		

Appendix B – Patient Evaluation

Thank you for participating in a study to evaluate the Theranos System. By utilizing the Theranos System you've been able to provide information to your physician that could support their decisions around your ongoing therapy.

We would like to ask you a few questions about your use of the Theranos System.

1. Overall, how easy was it to use the Theranos System?
    a. Very easy
    b. Somewhat easy
    c. Somewhat hard at first, but it got easier
    d. Very hard

2. How would you rate the Patient User Manual?
    a. Very informative, with clear directions
    b. Informative but some of the directions need to be clarified
    c. Not helpful at all
    d. Didn't read it
    e. Didn't get a patient user manual

3. How would you rate the training you received at the clinic prior to taking the System home?

    Very Good 10 9 8 7 6 5 4 3 2 1 Poor

4. How would you rate the Theranos System on the following attributes
    - Ease of use

        Very Easy 10 9 8 7 6 5 4 3 2 1 Hard

    - Time Required

        Very little time 10 9 8 7 6 5 4 3 2 1 Lots of time

    - Patient Diary

        Very easy to use 10 9 8 7 6 5 4 3 2 1 Hard to Use

    - Drawing Blood

        Painless 10 9 8 7 6 5 4 3 2 1 Painful

5. How well did the Theranos System work for you during the trial?
    a. Very Well
    b. Okay
    c. Had problems
        i. What problem(s) did you experience? Mark all that apply
            1. Drawing blood
            2. Filling the cartridge
            3. Loading the cartridge
            4. Getting a cellular signal
            5. Getting onto the website
            6. Filling out the patient diary
            7. Other (please explain)

ii. (For each problem) How were you able to resolve your problem on _____?
    1. Figured out solution on my own
    2. Called clinic and they helped me
    3. Called Theranos Customer Care Center
        a. How would you rate the support you received?
            i. Excellent
            ii. Very Good
            iii. Good
            iv. Fair
            v. Poor
        b. How was your problem resolved?
            i. Customer Care Center talked me through the problem
            ii. A replacement reader/cartridge was sent to me
            iii. Other (please explain)

6. Overall, on a scale of 1 to 10 which process would you prefer to provide monitoring information to your physician?

Prefer monitoring at home 10 9 8 7 6 5 4 3 2 1 Prefer going to clinic